Enzychem Lifesciences USA Inc. is a subsidiary company of Enzychem Lifesciences Inc., a Korea-based pharmaceutical company. Enzychem Lifesciences Inc. executes clinical trials for new drug development in the United States. Enzychem’s clinical program for its lead product candidate, EC-18, includes three Phase 2 clinical trials. The company is listed on the KOSDAQ stock exchange market and the current market cap is approximately $700M.
Enzychem Lifesciences USA Inc. is currently managing Enzychem Lifesciences’ US clinical trials, and developing strategies for IP protection and licensing. Learn more about the company and its work and priorities at http://www.enzychem.com/.